New MRI contrast agents show promise

Researchers at AAIC 2020 reported promising findings from preliminary studies of potential new MRI contrast agents for identifying early signs of neurodegeneration.

In one study, researchers performed a dose-ranging efficacy study of ADx-001, an amyloid-targeted liposomal macrocyclic gadolinium (Gd) contrast agent, for in vivo MRI of amyloid plaques in mice. They used a transgenic mouse model of early-onset Alzheimer’s disease, in which amyloid plaques develop from 6-7 months of age, and wide-type amyloid-negative controls.